In the phase 3 OCEANIC-STROKE trial, asundexian significantly reduced recurrent ischemic stroke risk compared with placebo without significantly increasing major bleeding. The Food and Drug ...

Asundexian plus antiplatelet therapy reduces IS risk in patients with noncardioembolic stroke or high-risk transient ischemic attack.

Because of the trust you have with your patients, you are in a unique position to notice, evaluate, and act on neurologic and other conditions your patients experience. As you are interacting with ...